SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.
Metrics to compare | SYNACT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSYNACTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.3x | −1.8x | −0.5x | |
PEG Ratio | −0.20 | −0.01 | 0.00 | |
Price/Book | 5.1x | 11.5x | 2.6x | |
Price / LTM Sales | - | 0.0x | 3.3x | |
Upside (Analyst Target) | 82.3% | 244.0% | 47.0% | |
Fair Value Upside | Unlock | −19.8% | 5.9% | Unlock |